ArticleInternational journal of nanomedicine2025
Si-ITGA6-Loaded Liposomes Inhibit Capsule Fibrosis via the FAK/PI3K/Akt Signaling Pathway in Adhesive Capsulitis of Shoulder.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fibroblast growth factor 9 activates fibroblast activation and drives the progress of shoulder stiffness.Frontiers in cell and developmental biology · 2025Article
- Macrophage-myofibroblast transition as a novel therapeutic target in shoulder stiffness: multi-omics study and experimental validation.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adhesive capsulitis of shoulder (ACS) is a common shoulder disease with pain, joint stiffness, and capsule fibrosis. The pathogenesis of ACS remains unclear, and long-term efficacy of current treatment for ACS is not satisfactory. Given the absence of targeted therapy, proteomic analysis is conducted on the capsules of ACS patients, in an effort to identify the potential target for ACS treatment. The liposome-based siRNA delivery system was utilized for in vivo experiments due to its non-immunogenicity, stability, and low off-target effects compared to other siRNA delivery methods. We aimed to provide a potential approach for targeted therapy of ACS. Methods: Capsules from rotator cuff tear (RCT) patients with or without ACS were collected. Proteomic analysis was performed to detect differentially expressed proteins. For in vitro experiments, EdU assay, wound healing assay, CCK-8, quantitative polymerase chain reaction, immunofluorescence staining and western blot was conducted. Histological, immunofluorescence and biomechanical assessments were utilized in a mouse model of ACS. The properties of siRNA-loaded liposomes were determined using laser particle size analyzer and electron microscopy. Results: Proteomic analysis identified integrin α6 (ITGA6) as a significantly upregulated protein in the capsules of RCT patients with ACS compared to those without ACS. ITGA6 promoted cell proliferation, migration ability, and pro-fibrotic proteins expression, while the blockade of ITGA6 exhibited anti-fibrotic effect. The regulatory effect of ITGA6 was dependent on FAK/PI3K/Akt signaling pathway. Finally, liposome was prepared to carry si-ITGA6, and this si-ITGA6-loaded liposomes demonstrated a potent therapeutic effect in a mouse model of ACS. After si-ITGA6-loaded liposomes injection, the capsule thickness was decreased from 120.3 ± 14.3 μm to 73.3 ± 12.6 μm (p < 0.01), and the ROM also improved from 81.0 ± 9.0 to 112.2 ± 8.1 degrees (p < 0.01). These results indicated that si-ITGA6-loaded liposomes significantly ameliorated capsule fibrosis and joint mobility without indication of toxicity. Conclusion: This research elucidated that ITGA6 was upregulated in the capsules of patients with ACS and is capable of significantly activating fibroblasts through the FAK/PI3K/Akt signaling pathway. By targeting ITGA6, si-ITGA6-loaded liposomes could effectively attenuate capsule fibrosis. In this study, we identified ITGA6 as a key regulator in ACS and demonstrated that targeting ITGA6 with siRNA-loaded liposomes effectively attenuated capsule fibrosis and improved joint mobility, offering a promising approach for targeted therapy of ACS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.